Dear Reader,

Welcome to the final issue of European Journal of Drug Metabolism and Pharmacokinetics for 2021.

I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.

In 2021, over 70 articles have been published. The most popular of these in terms of downloads from SpringerLink have been:

  • Deb S, Arrighi, S. Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. Eur J Drug Metab Pharmacokinet 46, 185–203 (2021). https://doi.org/10.1007/s13318-020-00668-8

  • Rubino CM, Onufrak NJ, van Ingen J, et al. Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease. Eur J Drug Metab Pharmacokinet 46, 277–287 (2021). https://doi.org/10.1007/s13318-020-00669-7

  • Veillette JJ, Winans SA, Maskiewicz VK, et al. Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients. Eur J Drug Metab Pharmacokinet 46, 385–394 (2021). https://doi.org/10.1007/s13318-021-00677-1

  • Haider MS, Ahmad T, Groll J, et al. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. Eur J Drug Metab Pharmacokinet 46, 575–593 (2021). https://doi.org/10.1007/s13318-021-00700-5

  • Würthwein G, Lanvers-Kaminsky C, Siebel C, et al. Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. Eur J Drug Metab Pharmacokinet 46, 289–300 (2021). https://doi.org/10.1007/s13318-021-00670-8

The high quality of content published in European Journal of Drug Metabolism and Pharmacokinetics has been reflected in the most recent impact factor of 2.441 and CiteScore™ of 4.1. Further, European Journal of Drug Metabolism and Pharmacokinetics has published content in a timely manner, with an average time from submission to first decision of 28 days.

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in European Journal of Drug Metabolism and Pharmacokinetics over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for European Journal of Drug Metabolism and Pharmacokinetics in the last 12 months:

Armina Abbasi, USA

Theresa Aliwarga, USA

Karel Allegaert, Belgium

Sean N. Avedissian, USA

Eleni Caratzas, Greece

Francesco Celandroni, Italy

Hardik Chandasana, USA

Wansheng Chen, China

Yang Chen, USA

Ann C. Childress, USA

Ananda Chowdhury, USA

Ranjeet P. Dash, USA

Antonio D'Avolio, Italy

Subrata Deb, USA

Jasper Dingemanse, Switzerland

Sreekanth Dittakavi, India

Duygu Durna Corum, Turkey

Gamal M. El Maghraby, Egypt

Liang Feng, USA

Zara Franklin, UK

Uwe Fuhr, Germany

Ryan S. Funk, USA

Yi Gu, USA

Evren Gundogdu, Turkey

Stefan Hagel, Ethiopia

Michael D. Hambuchen, USA

Daiki Hira, Japan

Masakiyo Hosokawa, Japan

Rita Humeniuk, USA

Rohitash Jamwal, USA

Zheng Jiao, China

Ekta Kadakia, USA

Shyam Kamble, USA

Isadore Kanfer, Canada

Siva Rama Raju Kanumuri, USA

Alptug Karakucuk, Turkey

Agnieszka Karbownik, Poland

Phisit Khemawoot, Thailand

Sonia Khier, France

Birgit Koch, the Netherlands

Priyanka Kulkarni, USA

Jaewi Lee, Republic of Korea

Dominique Leveque, France

Junyi Li, USA

Song-Lin Li, China

Gaofeng Liu, China

TaoTao Liu, China

Tao Long, USA

Sophie Magreault, France

Sherif H. Mahmoud, Canada

Amélie Marsot, Canada

Naoki Matsumoto, Japan

Litaty Mbatchi, France

Robert L. Medcalf, Australia

Aleksander Mendyk, Poland

Hirokazu Nakayama, Japan

Maria Neag, Romania

Mina Nikanjam, USA

Roberto Padrini, Italy

Guoyu Pan, China

Luciana Pereira Rangel, Brazil

Ana Ruiz-Garcia, USA

Madhav Sachar, USA

Antonin Schmitt, France

Satish Sharan, USA

Abhisheak Sharma, USA

Jian Shi, USA

Jaydeep Sinha, USA

Katarzyna Socha, Poland

Rui Song, China

Kannan Sridharan, Bahrain

Nuggehally R. Srinivas, USA

Rhishikesh Thakare, USA

Dandan Tian, USA

Vijayabhaskar Veeravalli, USA

Laiyou Wang, China

Sukyung Woo, USA

Matthew Wright, USA

Xin Wu, China

Hong-Guang Xie, China

Jun Xu, Hong Kong, China

Jaydeep Yadav, USA

Yoshiaki Yamamoto, Japan

Xinning Yang, USA

Bo Zheng, USA

I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.

Fanchon Bourasset, Paris, France

Soo Kyung Bae, Kyunggido, South Korea

Sagar S. Bachhav, Gainesville, FL, USA

Patrick Callery, Morgantown, WV, USA

Dario Cattaneo, Milan, Italy

Christian Cavé, Chatenay-Malabry, France

Salvatore Cisternino, Paris, France

Patrick M. Dansette, Paris, France

Jules Desmeules, Geneva, Switzerland

Padma V. Devarajan, Mumbai, India

Fawzy Elbarbry, Hillsboro, OR, USA

Robert Farinotti, Chatenay-Malabry, France

David Foster, Adelaide, Australia

Maria Jesus Garrido, Pamplona, Spain

Marko Goličnik, Ljubljana, Slovenia

Antonis Goulas, Thessaloniki, Greece

Tomasz Grabowski, Gdańsk, Poland

Olaf Grisk, Greifswald, Germany

Mounira Hamoudi, Lille, France

Sam Harirforoosh, Johnson City, TN, USA

Slobodan M. Jankovic, Kragujevic, Serbia

Vincent Jullien, Paris, France

Tony K. L. Kiang, Edmonton, AL, Canada

Ke Lan, Chengdu, Sichuan, China

Guo-Fu Li, Shanghai, Yangzhou, China

Weirong Li, Guangzhou, Guangdong, China

Momir Mikov, Novi Sad, Republic of Serbia

Steve Mitchell, London, UK

Fathi Moussa, Orsay Cedex, France

Gian Maria Pacifici, Pisa, Italy

Roberto Padrini, Padova, Italy

Scott R. Penzak, Fort Worth, TX, USA

Wei Ren, Guangzhou, Guangdong, China

Michael Weiss, Halle, Germany

Kyle J. Wilby, Halifax, NS, Canada

Springer Nature has continued to support the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, European Journal of Drug Metabolism and Pharmacokinetics has published a number of papers relevant to the COVID-19 pandemic that are free to access, including:

  • Tarek M, Savarino A. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. Eur J Drug Metab Pharmacokinet 45, 715–723 (2020). https://doi.org/10.1007/s13318-020-00640-6

  • Thémans P, Belkhir L, Dauby N, et al. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. Eur J Drug Metab Pharmacokinet 45, 703–713 (2020). https://doi.org/10.1007/s13318-020-00648-y

  • Deb S, Arrighi, S. Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. Eur J Drug Metab Pharmacokinet 46, 185–203 (2021). https://doi.org/10.1007/s13318-020-00668-8

In terms of other important company initiatives, the Springer Nature ‘Sustainable Development Goals (SDG) Programme’ is aiming to connect researchers who are tackling the world’s toughest challenges with practitioners in policy and business, while the ‘Women in Science’ initiative aims to help empower more women scientists to achieve scientific excellence. Finally, I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.

Returning to European Journal of Drug Metabolism and Pharmacokinetics, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles over the coming year.

I thank you for your continued support.

With best wishes,

Jasbir Singh